

# How Cannabis Affects the Body & the Brain

Karen M. Lounsbury, PhD

Peter R. Jackson, MD

October 2, 2018



The University of Vermont  
LARNER COLLEGE OF MEDICINE

# Outline:

Part I: Cannabis Effects on Pain and Pleasure Pathways

Dr. Karen Lounsbury

Part II: Cannabis and the Developing Brain

Dr. Peter Jackson




# Disclaimer

We are members of the faculty at the University of Vermont

Materials presented here represent our own research, views and opinions and are in no way a reflection of the legal views or opinions of the University of Vermont

Conflict of Interest: Pharmaceuticals will be presented according to their FDA approvals. We have no financial interests to disclose.

# Cannabis Effects on Pain and Pleasure Pathways




Karen M. Lounsbury, PhD

Professor of Pharmacology

Larner College of Medicine, University of Vermont

<https://www.youtube.com/watch?v=O5RdMvgk8b0>

# Cannabis: Medicine or Drug of Abuse?



# Cannabis and Phytocannabinoids





- *Cannabis sativa* produces many compounds that are secreted by trichomes in the flowers and leaves
- Different strains of *Cannabis* can produce different levels of biologically active components
  - Hemp
  - Charlotte's Web
  - Sativa/Indica



# Biologically Active Cannabinoids

*Cannabis* produces over 100 cannabinoids

- Delta-9-tetrahydrocannabinol (THC)
  - Partial Agonist CB1/CB2 receptors
  - Psychoactive
  - Anti-pain, anti-nausea
  - Anti-spasm, anti-inflammatory
- Cannabidiol (CBD)
  - Weak antagonist CB1/CB2 receptors
  - TRP channels or 5-HT receptors?
  - Not psychoactive, moderates THC
  - Anti-seizure activity, anti-pain activity
  - Possible non-receptor activities



- Activated by heating the plant (smoking, vaping, baking, heat extraction)

# Cannabis as a Medicine

- Proven effectiveness (THC):
  - Chronic Pain
  - Chemotherapy-induced Nausea
  - Seizures
  - Spasticity (MS and Cerebral Palsy)
  - Cachexia (wasting disorder)
- Likely effective and in clinical trials (THC):
  - Eating Disorders
  - Glaucoma
  - Anxiety Disorders (OCD, PTSD)
- Possibly effective, but needs more research (THC)
  - Addiction
  - Parkinson's/Alzheimer's
  - Inflammatory Diseases
  - Cancer

*Proven effectiveness is through randomized clinical trials using **THC**. Whole plant cannabis has been found effective for Pain, Nausea and Seizures, but these trials are sparse and nonexistent for other conditions.*

***CBD** has only been found effective against seizures, other trials have not shown significant effectiveness, but more are needed*

Lynch and Ware. Cannabinoids for the treatment of chronic non-cancer pain: An updated systematic review of randomized controlled trials. *Journal of Neuroimmune Pharmacology* 10: 293-301, 2015


Wilsey et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain*. 2008



# Your body makes its own cannabinoids

## Plant-derived cannabinoid

$\Delta^9$ -Tetrahydrocannabinol (THC)





## Endogenous cannabinoids

Anandamide (AEA)




2-Arachidonoylglycerol (2-AG)



Cannabinoid Receptors reduce neuronal activity in response to pain, nausea, and anxiety

- Both endocannabinoids and cannabis reduce both pain signal and interpretation of pain
- Similar to the action of opioids
  - Not as effective
  - Produce less tolerance
  - Less risk of addiction
  - Low risk of overdose




# Cannabis Intoxication:

- *Attributed to THC action in the brain*
- Head rush and euphoria (Reward Pathway)
- Appetite increase (Hypothalamus)
- Decreased attention, sedation (Hippocampus-Prefrontal cortex)
- Altered Perceptions (Pre-frontal cortex inhibition)
  - Awareness of the senses and of music may be increased
  - Distorted sense of time
  - Preoccupation with distractions
  - Giggles


## Brain regions that express the CB<sub>1</sub> cannabinoid receptor

Red = abundant CB<sub>1</sub> receptor expression    Black = moderately abundant CB<sub>1</sub> receptor expression





# Pre-frontal Cortex is primarily active in response to new experiences



# “Executive” functions of the Pre-frontal Cortex

- Planning, organization and execution of complex behavioral sequences (Working Memory)
- Flexible responses to changing environmental contingencies
- Selective attention, noticing change
- Persistence in a task despite distraction
- Creative problem solving

Perception is a combination of sensory input and pre-frontal cortex executive function





Through learning, we are able to distinguish errors in the environment



# Activities that can Reduce the Activity of Pre-Frontal Cortex

- Meditation
- Intense Exercise
  - Runner's High
  - reduction of pain sensations
  - widespread activation of motor and sensory systems during exercise shunts activity from the higher cognitive centers of the prefrontal cortex.
- Daydreaming
  - Frontal cortex is disengaged
  - Activities are controlled by automatic functions
  - Can perform complex automatic activities (like driving a normal route)
- Some Drugs of Abuse
  - Cannabis, Opioids

# Cannabis Effects on Attention: Impaired ability to drive



- Peripheral attention reduced
  - A person who is high may become absorbed in an object, event, or process to the exclusion of everything else
- Memory
  - Both short-term and long-term memory impairment
- Color/Image Perception
  - Hallucinogenic effects
- Motor Coordination
  - Impaired, but much less than alcohol or opioids

States with legalized recreational use have seen increased car accidents in the population that has combined alcohol and cannabis, but there is no significant difference in fatal car accidents in states with legalized cannabis

# Frontal Cortex Impairment: The Problem with Distractors

Stroop task: Identify the color of the words

RED

GREEN

RED

BLUE

BLUE

GREEN

BLUE

RED

Again: Identify the color of the words

**GREEN**

**BLUE**

**RED**

**BLUE**

**GREEN**

**RED**

**GREEN**

**BLUE**

Subjects intoxicated by THC have a much longer delay in completing the Stroop Test


# Cannabis Addiction in Perspective



- 30 million drugs are currently known
- Approximately 100 are addicting
- Many are natural products



- What properties make drugs addicting?






# Common Properties of Addicting Drugs


- Stimulate Dopamine signaling in the Reward Pathway
- Rapid acting, can get into the brain
- Withdrawal of drug inhibits the Reward Pathway
- Voluntarily administered (specifically to the reward center in animal models)
- Trigger relapse to drug-seeking behavior

# The Reward Pathway:



- Connects limbic regions of the brain
  - Ventral tegmental area
  - Nucleus accumbens
  - Pre-frontal cortex
- Dopamine receptor signaling tracts
- Overactivity is linked to psychologic addiction



# Effects of Addicting Drugs on DA signaling: Highjacking reward



# Cannabis Addiction Potential



# Young People are Particularly Vulnerable

- Substantially higher risk for Substance use disorder when an addicting drug is started before the age of 18, even higher risk with younger patients
- Chronic adverse effects of cannabis are more likely to develop in younger patients
- Dr. Jackson will now provide the viewpoint of a child psychiatrist

# Cannabis and the Developing Brain

Peter R Jackson, MD

Community Medical School

October 2, 2019




The University of Vermont  
LARNER COLLEGE OF MEDICINE



# Outline: Cannabis use and the teenage brain


- What's the trend?
- What's great (different) about the adolescent brain and why it matters
- Potential therapeutic benefits vs. well known risks
- A word to the parents in behalf of the kids
- Seeking solid ground

# National trends



Past 30 Day Alcohol, Marijuana, and Cigarette Use


Alcohol Marijuana Cigarettes



May 2018

VERMONT DEPARTMENT OF HEALTH

### Primary Methods Used to Consume Marijuana, Among Current Users



May 2018

VERMONT DEPARTMENT OF HEALTH



## Vermont trends: Middle school

Middle school students believing their parents would think it was wrong to:

Use alcohol: 85% (down from 91% in 2015)

Use marijuana: 92% (down from 94% in 2015)

Current middle school student marijuana use: 4% (unchanged)

# Vermont Trends: High School

High School students believing their parents would think it was wrong to:

Use alcohol: 66% (down from 72% in 2015)

Use marijuana: 76% (down from 80% in 2015)

Current high school student marijuana use: 24% (up from 22%)



# Vermont Trends: High School


High School students believing there is a great risk of harm from:

Binge drinking regularly: 36%

Smoking a pack or more of cigarettes: 68%

Using marijuana regularly: 24%

# Perception of harm and rates of use



# High school graduation isn't the finish line

A decorative graphic consisting of several overlapping wavy lines in various shades of green, spanning the width of the slide below the title.

# What's happening where recreational use is legal?

Those states have higher than average rates of adolescent use (they were already near the top)

Adolescent use trend is increasing in some states where legalized compared to holding steady for most states. (NSDUH) Conflicting studies abound


The rate of college age use, which is increasing nationally is increasing faster than the national average

Adolescent use rates correlate with availability (density of dispensaries: Colorado data)

Marketing targets all audiences, including young people

# Marketing






**at a child's birth**

**at 7 years of age**

**at 15 years of age**




# Brain development: Efficiency and connectivity






# Staggered development: Gas before brakes



## Substance Use Disorders Among Persons 12 and Older, by Age of First Use



Source: CASA analysis of the *National Household Survey on Drug Use and Health* (NSDUH), 2009.



## Higher risk for earlier use

4 to 7 times more likely to develop a use disorder if you use cannabis prior to age 18 compared to in adulthood. (Winters et al)

1 in 6 adolescents who use will develop a use disorder



# What's the upside... What's the downside?

---



# Adverse effects of early use

Negative impact on synaptic pruning and myelination

Cognitive effects:

- Verbal learning, recall, attention most impacted
- some studies showing measurable IQ decrease later in life (Meier et al)
- Some studies showing deficits improve after abstinence

Association with increased incidence of psychosis

Increase likelihood of anxiety disorders (Degenhardt et al)

Increased likelihood of depression (Rubino et al)

Amotivation, related to blunting of the dopaminergic system with chronic use (Bloomfield et al)

# Adverse effects of use: short term

Inattention

Impaired reaction time: doubled risk of car accident

Short term memory impairment



# Adverse effect of adolescent use: long term

Decreased white matter integrity: poorer connectivity

Poorer attention, processing speed, working memory

Impaired memory: decreased hippocampus volume

# Effect on the brain: Hot topics

## Cognition

Potential neuropsychological decline into the late 30s for adolescent users compared to adult onset use

Some studies show that this can recover with abstinence

## Motivation

Long term heavy use particularly associated with educational underachievement and impaired motivation

## Psychosis

Consistent association between adolescent cannabis use and psychosis. Could come from direct causality, gene-environment interaction, shared etiology.

# Medical Use of Cannabinoids in Children or Adolescents

Marijuana not FDA approved for the prevention or treatment of any disease process in kids

Evidence for cannabinoids

- Rare and severe forms of epilepsy: Recent FDA approval: Epidiolex (highly purified CBD) approved June 2018 for pediatrics seizures (Lennox Gastaut, Dravet Syndrome)
- Stronger signal: Chemotherapy induced nausea and vomiting (THC)
- Weaker signal/anecdotal: Tourette Syndrome, Spasticity, neuropathic pain, PTSD

“What should I tell parents about the medical benefits for adolescents or children?”

- Benefits have been primarily in case reports, risks are well established
- We will likely learn more as research continues

Note the process of prescribing any medication

- medication, dose, route, frequency

# American Academy of Pediatrics

- Opposes medical marijuana outside FDA process
- Opposes legalization for recreational use
- Supports research (move from schedule I to schedule II)
- Strict enforcement of rules against marketing and sale to children (age 21 minimum)
- Supports decriminalization for both adults and youth
- Opposes smoking in any form
- Strongly Discourages any use in the presence of children



# AMA position statement: Cannabinoid research

1. Study proposed/promising areas for benefit, see if we can expand the evidence from anecdotal to controlled trials
  1. Reconsider the schedule I status
  2. Put more funding towards it
2. Study the consequences of long term use, particularly in high risk groups
3. Don't legalize recreational use until we know more about the public health, medical, social and economic consequences of use

# AMA position statement: Legalization for medical use

1. Any treatment should be studied to assure safety
2. Should not be done through state legislative, referendum or ballot initiatives
3. Anything not approved labeled “marijuana has a high potential for abuse.”
4. Protect physicians working within state laws
5. Don't legalize recreational use until we know more about the public health, medical, social and economic consequences of use



# What aspects convey the highest risks?

Age of onset of use?

Frequency of use?

Duration of use?

Quantity used?

Strength/potency?


Composition (THC vs. CBD vs. other cannabinoids)?

# Teaching, Nurturing, Protecting


---




# Importance of Family




# Importance of Family



# Parenting Style



# Parental Influence





# Positive Parenting

Communication: calm and clear

Encouragement: of positive behaviors

Negotiation: working towards solution  
when conflict arises

Setting Limits: calmly and in  
proportion to behaviors

Supervision: know friends and  
schedule



# How do I talk about this with my kids?

Talk early, talk often

Talk with them when calm, not when angry or “high”

Stay calm but serious, not angry

Tell them what you’re worried about, then listen

ParentupVT.org (parent monitoring checklist, “Free marijuana talk kit”)

## Warning signs:


Mood and behavior changes: restlessness, paranoia, loss of interest

Rapid peer change and reluctance to introduce new peers

Notable drop in grades, declining participation in school

Significant change in concentration, memory lapses

# Genes and addiction



# For Parents

Actions speak louder than words

Words speak louder than no words

If substance use disorders have been a problem in the family, give good consideration to educating younger generations early on.

There ARE “sober kids” at school.

# Seeking Solid Ground

---



# How have we gotten here?

Grassroots activism



Pharmacological ingenuity

Private Profiteering

Policy moving ahead of science, with gaps in knowledge, underestimation of unintended consequences.

Volkow et. al, JAMA Psychiatry 2016

# Seeking Solid Ground



**Evidence Based Medicine:** when best evidence from research meets clinical information and patient values, optimal decisions are possible.

© MedPia.com





# Thank You

---





The University of Vermont

---

LARNER COLLEGE OF MEDICINE

# References:

Compton W, Thomas Y, Stinson F et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Arch Gen Psychiatry*/ Vol 64, May 2007; 45(11): 1294 - 1303

Geidd J The Amazing Teenage Brain. *Scientific American* **312**, 32 - 37 (2015)

Knight J, Shrier L, Bravender T et al., A new brief screen for adolescent substance abuse. *Arch Pediatr Adolesc Med* 1999; 153: 591-6

Merikangas K, Jian-Ping H, Burstein M et al. Lifetime prevalence of mental disorders in US adolescents: Results from the National Comorbidity Study-Adolescent Supplement (NCS-A) *J Am Acad Child Adolesc Psychiatry*. 2010 Oct; 49(10): 980–989.

Johnston LD, O'Malley PM, Miech RA, et al. (2016). Monitoring the future national survey results on drug use, 1975-2015: Overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan.

Schulenberg J, Johnston L, O'Malley P et al, Monitoring the Future national survey results on drug use, 1975-2016: Volume 2, College students and adults ages 19-55. Ann Arbor: Institute for Social Research, The University of Michigan, 2017

Olfson M, Wall M, Shiang-Min L, et al. Cannabis use and risk of prescription opioid use disorder in the United States, *Am J Psychiatry*, e pub Sept 2017

Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. *JAMA Psychiatry*. doi:10.1001/jamapsychiatry.2015.3229.

# References cont.

Bevilaqua L, Goldman D, Genes and Addictions, Clin Pharmacol Ther, 2009 Apr; 85(4): 359-361

Substance Abuse and Mental Health Services Administration. *Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings*. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013

Beaton A, Shubkin C, Chapman S. Addressing substance misuse in adolescents: a review of the literature on the screening, brief intervention, and referral to treatment model. Curr Opin Pediatr. 2016 Apr;28(2):258-65.

Waldron H, Kern-Jones S, Turner C. Engaging resistant adolescents in drug abuse treatment, Subst Abuse Treat. 2007 Mar; 32(2): 133-142

Ozechowski T, Becker S, Hogue A. SBIRT-A: adapting SBIRT to maximize developmental fit for adolescents in primary care. J Subst Abuse Treat. 2016 Mar; 62:28-37.

Schuman Olivier Z, Weiss D, Hoepfner B et al. Emerging adult status predicts poor buprenorphine treatment retention, J Subst Abuse Treat. 2014 Sep; 47(3): 202-212.

Winters KC, Lee C-YS. Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age. *Drug Alcohol Depend*. 2008;92(1-3):239-247.

Rubino T, Zamberletti E, Parolaro D et al, Adolescent exposure to cannabis as a risk factor for psychiatric disorders J Psychopharmacol. 2012 Jan;26(1):177-88. doi: 10.1177/0269881111405362. Epub 2011 Jul 18.

# References cont.

- Meier MH, Caspi A, Ambler A et al, Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012 Oct 2;109(40):E2657-64.
- Broyd S, Van Hell H, Beale C et al. Acute and chronic effects of cannabinoids on human cognition- a systematic review. *Biol Psychiatry*. 2016 Apr 1;79(7):557-67.
- Hanson K, Winward J, Schweinsburg A et al, Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. *Addict Behav*. 2010 Nov;35(11):970-6.
- Degenhardt L, Coffey C, Romaniuk H, The persistent of the association between adolescent cannabis use and common mental disorders into young adulthood. *Addiction*. 2013 Jan;108(1):124-33.
- Kandel D. Stages in adolescent involvement in drug use. *Science*. 1975;190(4217):912–914.
- Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: a national study. *Int J Drug Policy*. 2015;26(2):135–142.
- Kandel DB, Kandel ER. A molecular basis for nicotine as a gateway drug. *N Engl J Med*. 2014;371(21):2038–2039.
- Morrall AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. *Addiction*. 2002;97(12):1493–1504.
- Wagner FA, Anthony JC. Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. *Am J Epidemiol*. 2002;155(10):918–925.

# References cont.

Levy, S, Lorena M, Siqueira and the Committee on Substance Abuse, *Pediatrics* originally published online May 26, 2014;

Lubman D, Cheetham A, Yucel M et al, Cannabis and adolescent brain development, *Pharmacol Ther.* 2015 Apr;148:1-16. doi: 10.1016/j.pharmthera.2014.11.009. Epub 2014 Nov 20.

Pilowsky D, Wu L, Screening instruments for substance use and brief interventions targeting adolescents in primary care: A literature review. *Addict Behav.* 2013 May; 38(5): 2146–2153.

Wong S, Wilens T. Medical Cannabinoids in Children and Adolescents: A Systematic Review. *Pediatrics*, 2017; e20171818

Gray K, New Developments in understanding and treating adolescent marijuana dependence. *Adolesc Psychiatry (Hilversum)*. 2013 Oct 1; 3(4): 297–306

Volkow N et al, Effects of cannabis use on human behavior, including cognition, motivation, and psychosis, a review. *JAMA Psychiatry* 2016

Bloomfield et al, The effects of delta-9 tetrahydrocannabinol on the dopamine system. *Nature* 2016 Nov;539: 369-377

Lubman D, Cheetham A, Yucel M. Cannabis and adolescent brain development. *Pharmacol Ther.* 2015; 148:1-16.

Dishion T, Nelson S, Kavanagh K. The family check-up with high-risk adolescents: Preventing early-onset substance use by parent monitoring. *Behav Ther.*2003;34(4):553-571



The University of Vermont

---

LARNER COLLEGE OF MEDICINE

Peter R Jackson, MD | Assistant Professor of Psychiatry | [peter.jackson@uvmhealth.org](mailto:peter.jackson@uvmhealth.org)